drugset / Trial / NCT00111579

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

NCT00111579

Phase 2 Completed 52 enrolled MedImmune LLC
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.

Timeline

Start
2005-05
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator FluMist Vaccine 0.2 ml Intranasal

Indications